AstraZeneca
AZN
965 hedge funds and large institutions have $28.4B invested in AstraZeneca in 2022 Q3 according to their latest regulatory filings, with 80 funds opening new positions, 379 increasing their positions, 316 reducing their positions, and 112 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 379 | Existing positions reduced: 316
0.31% less ownership
Funds ownership: 17.06% → 16.75% (-0.31%)
5% less funds holding
Funds holding: 1,015 → 965 (-50)
11% less call options, than puts
Call options by funds: $337M | Put options by funds: $378M
18% less capital invested
Capital invested by funds: $34.8B → $28.4B (-$6.43B)
29% less first-time investments, than exits
New positions opened: 80 | Existing positions closed: 112
38% less funds holding in top 10
Funds holding in top 10: 24 → 15 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM Investment Management
Laguna Beach,
California
|
+$307M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$250M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$211M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$202M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$180M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$789M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$668M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$279M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$218M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$199M |
AZN Hedge Fund Activity: Q3 2022 in Review
965 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2022, worth a combined $28.4B — down 18% from $34.8B a quarter earlier.
Sellers outnumbered buyers: 112 funds closed out of AZN and 80 opened new positions — a net loss of 32 holders — while 316 trimmed existing stakes and 379 added.
The largest buyer was WCM Investment Management, adding an estimated $307M. The largest seller was Fisher Asset Management, cutting an estimated $789M.
- 965 institutional investors held AstraZeneca (AZN) as of Q3 2022, down from 1,015 in Q2 2022.
- Funds reported $28.4B of AstraZeneca stock for Q3 2022, down 18% quarter-over-quarter.
- 80 funds opened new AstraZeneca positions in Q3 2022 and 112 closed out, a net change of -32 holders.
- The largest AstraZeneca buyer in Q3 2022 was WCM Investment Management, an estimated $307M added.
- The largest AstraZeneca seller in Q3 2022 was Fisher Asset Management, an estimated $789M sold.
Based on aggregated 13F filings for Q3 2022.